During phase I treatment with MK-2206, a pan-AKT inhibitor, a dramatic 23% shrinkage in tumor was found in a patient with a loss of PTEN KRAS-dependent PDAC, which was thought to have occurred via PI3K–AKT–mTOR inhibition (43). This evidence concerns the gene KRAS and neoplasm.